The Market Reports

Index

1 PD-1 and PDL-1 Inhibitors Market Overview
1.1 Product Overview and Scope of PD-1 and PDL-1 Inhibitors
1.2 PD-1 and PDL-1 Inhibitors Segment by Type
1.2.1 Global PD-1 and PDL-1 Inhibitors Market Value Comparison by Type (2023-2029)
1.2.2 Pembrolizumab
1.2.3 Nivolumab
1.2.4 Atezolizumab
1.2.5 Durvalumab
1.2.6 Avelumab
1.3 PD-1 and PDL-1 Inhibitors Segment by Application
1.3.1 Global PD-1 and PDL-1 Inhibitors Market Value by Application: (2023-2029)
1.3.2 Stomach Cancer
1.3.3 Liver Cancer
1.3.4 Kidney Ccancer
1.3.5 Bladder Cancer
1.3.6 Cervical Cancer
1.3.7 Other
1.4 Global PD-1 and PDL-1 Inhibitors Market Size Estimates and Forecasts
1.4.1 Global PD-1 and PDL-1 Inhibitors Revenue 2018-2029
1.4.2 Global PD-1 and PDL-1 Inhibitors Sales 2018-2029
1.4.3 Global PD-1 and PDL-1 Inhibitors Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 PD-1 and PDL-1 Inhibitors Market Competition by Manufacturers
2.1 Global PD-1 and PDL-1 Inhibitors Sales Market Share by Manufacturers (2018-2023)
2.2 Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Manufacturers (2018-2023)
2.3 Global PD-1 and PDL-1 Inhibitors Average Price by Manufacturers (2018-2023)
2.4 Global PD-1 and PDL-1 Inhibitors Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of PD-1 and PDL-1 Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of PD-1 and PDL-1 Inhibitors, Product Type & Application
2.7 PD-1 and PDL-1 Inhibitors Market Competitive Situation and Trends
2.7.1 PD-1 and PDL-1 Inhibitors Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest PD-1 and PDL-1 Inhibitors Players Market Share by Revenue
2.7.3 Global PD-1 and PDL-1 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 PD-1 and PDL-1 Inhibitors Retrospective Market Scenario by Region
3.1 Global PD-1 and PDL-1 Inhibitors Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global PD-1 and PDL-1 Inhibitors Global PD-1 and PDL-1 Inhibitors Sales by Region: 2018-2029
3.2.1 Global PD-1 and PDL-1 Inhibitors Sales by Region: 2018-2023
3.2.2 Global PD-1 and PDL-1 Inhibitors Sales by Region: 2024-2029
3.3 Global PD-1 and PDL-1 Inhibitors Global PD-1 and PDL-1 Inhibitors Revenue by Region: 2018-2029
3.3.1 Global PD-1 and PDL-1 Inhibitors Revenue by Region: 2018-2023
3.3.2 Global PD-1 and PDL-1 Inhibitors Revenue by Region: 2024-2029
3.4 North America PD-1 and PDL-1 Inhibitors Market Facts & Figures by Country
3.4.1 North America PD-1 and PDL-1 Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America PD-1 and PDL-1 Inhibitors Sales by Country (2018-2029)
3.4.3 North America PD-1 and PDL-1 Inhibitors Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe PD-1 and PDL-1 Inhibitors Market Facts & Figures by Country
3.5.1 Europe PD-1 and PDL-1 Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe PD-1 and PDL-1 Inhibitors Sales by Country (2018-2029)
3.5.3 Europe PD-1 and PDL-1 Inhibitors Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific PD-1 and PDL-1 Inhibitors Market Facts & Figures by Country
3.6.1 Asia Pacific PD-1 and PDL-1 Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific PD-1 and PDL-1 Inhibitors Sales by Country (2018-2029)
3.6.3 Asia Pacific PD-1 and PDL-1 Inhibitors Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America PD-1 and PDL-1 Inhibitors Market Facts & Figures by Country
3.7.1 Latin America PD-1 and PDL-1 Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America PD-1 and PDL-1 Inhibitors Sales by Country (2018-2029)
3.7.3 Latin America PD-1 and PDL-1 Inhibitors Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa PD-1 and PDL-1 Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa PD-1 and PDL-1 Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa PD-1 and PDL-1 Inhibitors Sales by Country (2018-2029)
3.8.3 Middle East and Africa PD-1 and PDL-1 Inhibitors Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global PD-1 and PDL-1 Inhibitors Sales by Type (2018-2029)
4.1.1 Global PD-1 and PDL-1 Inhibitors Sales by Type (2018-2023)
4.1.2 Global PD-1 and PDL-1 Inhibitors Sales by Type (2024-2029)
4.1.3 Global PD-1 and PDL-1 Inhibitors Sales Market Share by Type (2018-2029)
4.2 Global PD-1 and PDL-1 Inhibitors Revenue by Type (2018-2029)
4.2.1 Global PD-1 and PDL-1 Inhibitors Revenue by Type (2018-2023)
4.2.2 Global PD-1 and PDL-1 Inhibitors Revenue by Type (2024-2029)
4.2.3 Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Type (2018-2029)
4.3 Global PD-1 and PDL-1 Inhibitors Price by Type (2018-2029)
5 Segment by Application
5.1 Global PD-1 and PDL-1 Inhibitors Sales by Application (2018-2029)
5.1.1 Global PD-1 and PDL-1 Inhibitors Sales by Application (2018-2023)
5.1.2 Global PD-1 and PDL-1 Inhibitors Sales by Application (2024-2029)
5.1.3 Global PD-1 and PDL-1 Inhibitors Sales Market Share by Application (2018-2029)
5.2 Global PD-1 and PDL-1 Inhibitors Revenue by Application (2018-2029)
5.2.1 Global PD-1 and PDL-1 Inhibitors Revenue by Application (2018-2023)
5.2.2 Global PD-1 and PDL-1 Inhibitors Revenue by Application (2024-2029)
5.2.3 Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Application (2018-2029)
5.3 Global PD-1 and PDL-1 Inhibitors Price by Application (2018-2029)
6 Key Companies Profiled
6.1 GlaxoSmithKline plc
6.1.1 GlaxoSmithKline plc Corporation Information
6.1.2 GlaxoSmithKline plc Description and Business Overview
6.1.3 GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.1.4 GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Product Portfolio
6.1.5 GlaxoSmithKline plc Recent Developments/Updates
6.2 Bristol-Myers Squibb Company
6.2.1 Bristol-Myers Squibb Company Corporation Information
6.2.2 Bristol-Myers Squibb Company Description and Business Overview
6.2.3 Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Product Portfolio
6.2.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.3 Arcus Biosciences, Inc.
6.3.1 Arcus Biosciences, Inc. Corporation Information
6.3.2 Arcus Biosciences, Inc. Description and Business Overview
6.3.3 Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Product Portfolio
6.3.5 Arcus Biosciences, Inc. Recent Developments/Updates
6.4 Agenus Inc
6.4.1 Agenus Inc Corporation Information
6.4.2 Agenus Inc Description and Business Overview
6.4.3 Agenus Inc PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Agenus Inc PD-1 and PDL-1 Inhibitors Product Portfolio
6.4.5 Agenus Inc Recent Developments/Updates
6.5 F. Hoffmann-La Roche Ltd
6.5.1 F. Hoffmann-La Roche Ltd Corporation Information
6.5.2 F. Hoffmann-La Roche Ltd Description and Business Overview
6.5.3 F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.5.4 F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Product Portfolio
6.5.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
6.6 Astra Zeneca PLC
6.6.1 Astra Zeneca PLC Corporation Information
6.6.2 Astra Zeneca PLC Description and Business Overview
6.6.3 Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Product Portfolio
6.6.5 Astra Zeneca PLC Recent Developments/Updates
6.7 Beigene Ltd
6.6.1 Beigene Ltd Corporation Information
6.6.2 Beigene Ltd Description and Business Overview
6.6.3 Beigene Ltd PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Beigene Ltd PD-1 and PDL-1 Inhibitors Product Portfolio
6.7.5 Beigene Ltd Recent Developments/Updates
6.8 Incyte Corporation
6.8.1 Incyte Corporation Corporation Information
6.8.2 Incyte Corporation Description and Business Overview
6.8.3 Incyte Corporation PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Incyte Corporation PD-1 and PDL-1 Inhibitors Product Portfolio
6.8.5 Incyte Corporation Recent Developments/Updates
6.9 Biocad
6.9.1 Biocad Corporation Information
6.9.2 Biocad Description and Business Overview
6.9.3 Biocad PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Biocad PD-1 and PDL-1 Inhibitors Product Portfolio
6.9.5 Biocad Recent Developments/Updates
6.10 CStone Pharmaceuticals
6.10.1 CStone Pharmaceuticals Corporation Information
6.10.2 CStone Pharmaceuticals Description and Business Overview
6.10.3 CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.10.4 CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Product Portfolio
6.10.5 CStone Pharmaceuticals Recent Developments/Updates
6.11 Ono Pharmaceutical
6.11.1 Ono Pharmaceutical Corporation Information
6.11.2 Ono Pharmaceutical PD-1 and PDL-1 Inhibitors Description and Business Overview
6.11.3 Ono Pharmaceutical PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Ono Pharmaceutical PD-1 and PDL-1 Inhibitors Product Portfolio
6.11.5 Ono Pharmaceutical Recent Developments/Updates
6.12 Merck
6.12.1 Merck Corporation Information
6.12.2 Merck PD-1 and PDL-1 Inhibitors Description and Business Overview
6.12.3 Merck PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Merck PD-1 and PDL-1 Inhibitors Product Portfolio
6.12.5 Merck Recent Developments/Updates
6.13 Shanghai Junshi Bioscience Co. Ltd
6.13.1 Shanghai Junshi Bioscience Co. Ltd Corporation Information
6.13.2 Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Description and Business Overview
6.13.3 Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Product Portfolio
6.13.5 Shanghai Junshi Bioscience Co. Ltd Recent Developments/Updates
6.14 Shanghai Henlius Biotech, Inc.
6.14.1 Shanghai Henlius Biotech, Inc. Corporation Information
6.14.2 Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Description and Business Overview
6.14.3 Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Product Portfolio
6.14.5 Shanghai Henlius Biotech, Inc. Recent Developments/Updates
6.15 Jiangsu HengRui Medicine Co., Ltd.
6.15.1 Jiangsu HengRui Medicine Co., Ltd. Corporation Information
6.15.2 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Description and Business Overview
6.15.3 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Product Portfolio
6.15.5 Jiangsu HengRui Medicine Co., Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 PD-1 and PDL-1 Inhibitors Industry Chain Analysis
7.2 PD-1 and PDL-1 Inhibitors Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 PD-1 and PDL-1 Inhibitors Production Mode & Process
7.4 PD-1 and PDL-1 Inhibitors Sales and Marketing
7.4.1 PD-1 and PDL-1 Inhibitors Sales Channels
7.4.2 PD-1 and PDL-1 Inhibitors Distributors
7.5 PD-1 and PDL-1 Inhibitors Customers
8 PD-1 and PDL-1 Inhibitors Market Dynamics
8.1 PD-1 and PDL-1 Inhibitors Industry Trends
8.2 PD-1 and PDL-1 Inhibitors Market Drivers
8.3 PD-1 and PDL-1 Inhibitors Market Challenges
8.4 PD-1 and PDL-1 Inhibitors Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer